Board meeting on Nov 7 to consider Q2 FY27 results

Results View source PDF Explain this filing

DIVISLAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.3%Reaction day

₹9162.00

prior close

₹9165.00

announcement price

After-mkt

timing

Nifty 100market-0.7%-1.6% vs market

Pharmaceuticals peers, median of 170sector-1.5%-0.8% vs sector

On the reaction day the stock moved 1.6 pts less than Nifty 100 and 0.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.6

15m

-0.5

30m

-1.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.3-0.7-1.6-1.5-0.8

Next day

-1.2-0.0-1.2-0.4-0.8

+3.7+0.2+3.5+1.5+2.2

+4.6pendingpending+2.5+2.1

—————

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 170Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Divi's Laboratories has informed exchanges that its Board of Directors will meet on Saturday, November 7, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026 (Q2 and H1 FY27). The trading window for dealing in the company's securities is already closed and will remain closed till November 9, 2026, that is 48 hours after results are declared.

Likely market impact

Routine advance intimation; no material action for shareholders until the results are announced on Nov 7.